Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
NEW ORLEANS, Feb. 05, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 4, 2016 to file lead plaintiff applications in a securities class action lawsuit against Insys Therapeutics, Inc. (Nasdaq:INSY), if they purchased the Company’s securities between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona.
What You May Do
If you purchased shares of Insys and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 4, 2016.
About the Lawsuit
Insys and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements included, but are not limited to, that: (i) Insys was engaged in the illegal and improper off-labeling marketing of Subsys; (ii) certain Insys employees—including the President and Chief Executive Officer of Insys during much of the Class Period—were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, Insys’s financial statements were materially false and misleading at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
